7 health tech startups flock to Houston for TMC bootcamp

ready to accelerate

Texas Medical Center Innovation announced the seven health tech startups that joined the 2022 accelerator bootcamp. Photo courtesy of TMC

The Texas Medical Center's innovation arm welcomed seven companies to its 2022 health tech accelerator program bootcamp.

TMC Innovation Accelerator for HealthTech is aimed at supporting early-stage life science startups through fundraising, connecting with mentors and potential customers, and more.

“Healthtech startups who connect with our network will emerge more prepared to access their customers and grow into their markets," says Emily Reiser, associate director of TMC Innovation, in a news release. "Our advisors, members, and partners unlock insights for these entrepreneurs about how to more effectively build a strategic plan for improved market access and adoption. Bootcamp ignites these connections, providing immediate value to entrepreneurs and enabling our team to define a long term plan for continued collaboration."

If selected following the bootcamp, founders will spend six months at TMCi with strategic mentorship, clinical validation, and other customized milestone development from the organization.

“Bootcamp is an intensive period of discovery and mutual selection," says Devin Dunn, head of the Accelerator for HealthTech, in the release. "Founders get a chance better understand everything that TMCi brings to bear and our team has the opportunity to select those growing companies that will add significant value to our community.”

The bootcamp focused on several innovation areas — including surgical devices, access to care, robotics, and hospital efficiency. The participating companies include:

  • CardMedic, headquartered in Oxford, United Kingdom, aims to improve communication between staff and patients across any barrier-language, deafness, cognitive impairment or disability-with an A to Z library of pre-written scripts replicating common clinical conversations.
  • Chicago-baseed CareAdvisors is connecting health plans, hospitals, and community-based organizations to streamline high risk case management and quickly close the loop on care.
  • Endolumik, founded in Morgantown, West Virginia, has developed a fluorescence-guided device that uses near-infrared light to enhance visualization for safer, faster, and more consistent bariatric surgery.
  • Orcha, based in Daresbury, United Kingdom, rigorously reviews apps to help systems, clinicians, patients, or consumers find their way to the best health-related apps.
  • Austin-based Roboligent has created a rehabilitation robot, the Optimo Regen, that provides evidence-based therapeutic interventions for upper and lower limbs.
  • Boston-founded ScienceIO's platform transforms unstructured text into structured records in real-time. The company's core product is a HIPAA-compliant API for real-time text processing and analytics.
  • Semantic Health, founded in Toronto, Canada, uses artificial intelligence to complete secondary reviews of all coded and claims data to optimize revenue cycle management.
The application for future cohorts and more information about the program are available online. The 2022 cohort will join the ranks of TMCi's community of 305 life science startups and 221 TMC Innovation Accelerator companies and will receive access to the center's dozens of member organizations.

"Having a product that the market truly needs is critical but not enough," says Bongsu Kim, founder and CEO of Roboligent, in the release. "Especially for the medical device market, I realize that introducing a new product is a thorough and collaborative effort from a variety of stakeholders and experts. Without knowing the mechanism and the right connection, it seems almost impossible to get into the market. The TMC Innovation Accelerator is the perfect place to make it happen."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.

New Texas Stock Exchange officially begins trading in Dallas

Welcome to Y'all Street

Two-step aside, New York Stock Exchange and Nasdaq. The Dallas-based Texas Stock Exchange, nicknamed Y’all Street, just kicked off live trading with five stocks — and lots of Lone Star ambition.

“The Texas Stock Exchange aims to revitalize competition for [stock] issuers, establish the premier venue for listings, and create a world-class trading platform for all market participants,” the exchange says in a fact sheet.

The exchange — whose Texas-influenced nickname is a nod to New York City’s Wall Street — has collected at least $275 million in investments. The roughly 90 financial backers of TXSE include Bank of America, BlackRock, Charles Schwab, Citadel Securities, Dell Family Office, Fortress, Goldman Sachs, and JPMorgan Chase.

Representatives of TXSE couldn’t be reached for comment. On its website, the exchange calls itself “the most well-capitalized equities exchange to ever be approved” by the U.S. Securities and Exchange Commission (SEC).

Not to be outdone, NYSE has launched Dallas-based NYSE Texas and Nasdaq has expanded its presence in Dallas.

Y’all Street adds to Dallas-Fort Worth’s rising status as a major hub for financial services, with The Wall Street Journal naming North Texas the country’s second biggest financial hub after New York City.

“A homegrown national exchange means more jobs, more investment, and more growth opportunities for businesses and communities across the Lone Star State,” Gabriela von zur Muehlen, senior vice president and chief policy officer at the Texas Association of Business, told The Texas Tribune.

Bulent Temel, an associate professor of practice in economics at the University of Texas at San Antonio, told Texas Standard that TXSE “is going to boost the credibility of the Texas economy.”

Texas’ estimated gross domestic product (GDP), a yardstick for the size of an economy, climbed to a record-setting $2.9 trillion in 2025, making it the state with the second highest GDP after California. DFW’s estimated GDP in 2023 stood at $744.6 billion, eclipsing the GDP of many countries.

“The center of gravity for American capitalism is now headquartered in the Boom Belt,” Abbott proclaimed in April, referring to an 11-state region (including Texas) in the South and Southeast that’s seeing tremendous economic and population growth. “The Texas Stock Exchange is the natural extension of that capitalism. It ensures that capital markets will reflect the quadrant that is driving American growth.”

---

This article originally appeared on CultureMap.com.

Orion vehicle manager reflects on Artemis II, looks to 2028 moon mission

Q&A

Humanity is finally headed back to the moon after more than half a century. This year's launch of the Artemis II mission in the Orion spacecraft put four crew members in lunar orbit and tested the new ship developed by Lockheed Martin.

Everything went smoothly, safely returning astronauts home, but there is always room to improve. InnovationMap chatted via email with Orion vehicle manager Branelle Rodriguez, shortly after a talk at The Ion, for insight on how Orion might perform in the future as the next lunar landing approaches in early 2028.

InnovationMap: How satisfied are you with the way Orion operated on this past mission?

Branelle Rodriguez: Orion performed exceptionally well during Artemis II, successfully demonstrating critical spacecraft capabilities, including life support systems, displays and controls, and executing manual piloting operations. Artemis II brought humans back to the moon, achieving key exploration and scientific imagery, while validating systems essential for future Artemis missions.

IM: What is the most important thing you learned about improving Orion for the next mission?

BR: The Artemis II mission provided invaluable insights into crew operations and spacecraft performance in a deep-space environment. With every mission, NASA applies lessons learned to continuously improve Orion’s operations, validate design and ensure mission readiness. Artemis II offered our first opportunity to evaluate several new systems and gain a deeper understanding of what it is like for astronauts to live and work inside the spacecraft. The operational, technical and human factors data collected are being integrated across the program to refine future missions, reduce risk and enhance overall mission success.

IM: How has Orion helped the mission to explore space?

BR: Orion is one of NASA’s foundational elements for human deep space exploration—not only supporting the mission but serving as a core component of it. It is currently the only spacecraft capable of carrying crew on deep space missions and returning them safely to Earth from the high speeds required from the vicinity of the moon. No other spacecraft has the technology to endure the extremes that come with human deep-space travel, such as advanced environmental and life support, navigation, communications, radiation shielding, and the world’s largest ablative heat shield to protect the astronauts during reentry into Earth’s atmosphere. Orion has already taken astronauts to explore space farther than ever before—252,756 miles from Earth— and will carry crews to the moon on future missions to explore the lunar South Pole region. The astronauts’ observations, samples, and data collected on these future missions will expand our understanding of our solar system and home planet.

---

This conversation has been edited for brevity and clarity.

View All Listings